Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant MAP vs AP Chemotherapy in Adult Osteosarcoma
NCT05057130Phase 3Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in osteosarcoma (OS) (2 arms), sponsored by N.N. Blokhin Russian Cancer Research Center. Primary endpoint: Overall Response Rate at 6 months. Started Jan 2022; status: recruiting.
02
Drugs
methotrexate
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05057130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057130.